Cardioxyl Pharmaceuticals (Chapel Hill, NC), a clinical stage pharmaceutical company utilizing its proprietary nitroxyl chemistry platform to discover and develop novel therapeutics to treat cardiovascular disease, closed a $28M Series B financing. Participants include OrbiMed Advisors, Osage University Partners, New Enterprise Associates and The Aurora Funds.